Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD

14.54  -0.06 (-0.41%)

After market: 14.58 +0.04 (+0.28%)

Fundamental Rating

2

LQDA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LQDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LQDA had negative earnings in the past year.
LQDA had a negative operating cash flow in the past year.
In the past 5 years LQDA always reported negative net income.
In the past 5 years LQDA always reported negative operating cash flow.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of LQDA (-56.21%) is worse than 64.77% of its industry peers.
LQDA has a worse Return On Equity (-257.14%) than 73.06% of its industry peers.
Industry RankSector Rank
ROA -56.21%
ROE -257.14%
ROIC N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

With a decent Gross Margin value of 58.08%, LQDA is doing good in the industry, outperforming 67.36% of the companies in the same industry.
In the last couple of years the Gross Margin of LQDA has declined.
LQDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LQDA has more shares outstanding
The number of shares outstanding for LQDA has been increased compared to 5 years ago.
The debt/assets ratio for LQDA is higher compared to a year ago.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

LQDA has an Altman-Z score of -0.63. This is a bad value and indicates that LQDA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.63, LQDA perfoms like the industry average, outperforming 49.74% of the companies in the same industry.
A Debt/Equity ratio of 2.08 is on the high side and indicates that LQDA has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.08, LQDA is doing worse than 77.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.08
Debt/FCF N/A
Altman-Z -0.63
ROIC/WACCN/A
WACC9.87%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

LQDA has a Current Ratio of 2.93. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
LQDA has a Current ratio of 2.93. This is comparable to the rest of the industry: LQDA outperforms 49.74% of its industry peers.
A Quick Ratio of 2.91 indicates that LQDA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.91, LQDA is in line with its industry, outperforming 53.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.91
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

LQDA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.28%.
LQDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.45%.
The Revenue has been growing by 11.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)-11.45%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%4.98%

3.2 Future

LQDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.56% yearly.
The Revenue is expected to grow by 106.17% on average over the next years. This is a very strong growth
EPS Next Y3.44%
EPS Next 2Y35.77%
EPS Next 3Y35.55%
EPS Next 5Y23.56%
Revenue Next Year149.88%
Revenue Next 2Y254.46%
Revenue Next 3Y174.69%
Revenue Next 5Y106.17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LQDA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as LQDA's earnings are expected to grow with 35.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.77%
EPS Next 3Y35.55%

More info and screens

0

5. Dividend

5.1 Amount

LQDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIQUIDIA CORP

NASDAQ:LQDA (7/18/2025, 8:00:01 PM)

After market: 14.58 +0.04 (+0.28%)

14.54

-0.06 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-07 2025-08-07/amc
Inst Owners63.22%
Inst Owner Change0.01%
Ins Owners3.74%
Ins Owner Change0.87%
Market Cap1.24B
Analysts82.5
Price Target31.42 (116.09%)
Short Float %29.88%
Short Ratio8.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.71%
Min EPS beat(2)-20.44%
Max EPS beat(2)-10.99%
EPS beat(4)1
Avg EPS beat(4)-4.06%
Min EPS beat(4)-20.44%
Max EPS beat(4)21.21%
EPS beat(8)1
Avg EPS beat(8)-35.5%
EPS beat(12)4
Avg EPS beat(12)-16.3%
EPS beat(16)5
Avg EPS beat(16)-21.05%
Revenue beat(2)0
Avg Revenue beat(2)-22.07%
Min Revenue beat(2)-37.8%
Max Revenue beat(2)-6.33%
Revenue beat(4)1
Avg Revenue beat(4)-25.52%
Min Revenue beat(4)-62.04%
Max Revenue beat(4)4.12%
Revenue beat(8)2
Avg Revenue beat(8)-19.09%
Revenue beat(12)5
Avg Revenue beat(12)-8.64%
Revenue beat(16)9
Avg Revenue beat(16)0.92%
PT rev (1m)4.76%
PT rev (3m)15.02%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)-4.02%
EPS NY rev (1m)-0.32%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)1.84%
Revenue NQ rev (3m)-19.62%
Revenue NY rev (1m)-5.6%
Revenue NY rev (3m)-9.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.87
P/FCF N/A
P/OCF N/A
P/B 25
P/tB 29.11
EV/EBITDA N/A
EPS(TTM)-1.58
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.17
BVpS0.58
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.21%
ROE -257.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.08%
FCFM N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 2.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 377.72%
Cap/Sales 57.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.91
Altman-Z -0.63
F-Score1
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y3.44%
EPS Next 2Y35.77%
EPS Next 3Y35.55%
EPS Next 5Y23.56%
Revenue 1Y (TTM)-11.45%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%4.98%
Revenue Next Year149.88%
Revenue Next 2Y254.46%
Revenue Next 3Y174.69%
Revenue Next 5Y106.17%
EBIT growth 1Y-37.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-280.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-263.9%
OCF growth 3YN/A
OCF growth 5YN/A